Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05244239

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

A Phase I Study of Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

Sponsor: Emory University

Conditions Extensive Stage Lung Small Cell Carcinoma Stage IV Lung Cancer AJCC v8

Interventions Lurbinectedin Palliative Radiation Therapy

Updated 9 times since 2022 Last updated: Oct 29, 2025 Started: Jul 27, 2022 Primary completion: Jul 28, 2026 Completion: Jul 28, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05244239, this PHASE1 trial focuses on Extensive Stage Lung Small Cell Carcinoma and Stage IV Lung Cancer AJCC v8 and remains actively recruiting participants. Sponsored by Emory University, it has been updated 9 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE1
Mar 2025 — Nov 2025 [monthly]

Recruiting PHASE1
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 4 earlier versions

Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Feb 2023 — Feb 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
May 2022 — Feb 2023 [monthly]

Not Yet Recruiting PHASE1
Mar 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emory University
Jazz Pharmaceuticals
National Cancer Institute (NCI)

Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States